Newsroom

INTERVIEW

THE BIO

December 1, 2025

Galux claims ‘one-day antibody design’ as it enters the global top-three AI race

Read More

NEWS

November 26, 2025

Galux Achieves Breakthrough by Delivering High-Affinity De Novo Antibodies from Only 50 AI Designs, Marking a New Era in Precision Protein Design

Read More

NEWS

November 14, 2025

Galux and ISU Abxis Sign MOU to Collaborate on AI-Driven Drug Discovery

Read More

NEWS

September 30, 2025

Galux and Woojung Bio Forge Strategic Partnership to Accelerate AI-Driven Therapeutics Development

Read More

NEWS

September 23, 2025

Galux Demonstrates De Novo Antibody Design With Structural and Functional Validation Across Eight Targets

Read More

MEDIA

THE PHARMACEUTICAL JOURNAL

August 22, 2025

Designed by AI: the future of antibody drugs

Read More

NEWS

June 11, 2025

Galux and HanAll Biopharma Initiate Strategic Collaboration to Develop AI-Designed Antibody Therapeutics for Cancer

Read More

INTERVIEW

KOREATECHDESK

May 26, 2025

Pioneering Precision: How South Korea's Galux is Redefining Antibody Discovery with AI

Read More

INTERVIEW

CHOSUN BIZ

March 20, 2025

Korean AI firm Galux develops six novel therapeutic antibodies using innovative design methods

Read More

INTERVIEW

KBR

March 20, 2025

[Interview] DeepMind predicted proteins. A Korean startup says it's designing the future of antibodies.

Read More

NEWS

March 17, 2025

Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets

Read More

MEDIA

THE BIO

March 13, 2025

Y-Biologics and Galux to co-develop AI-driven immune anticancer treatment

Read More